Scientists develop screening method for pancreatic cancer

September 20, 2005

Scientists at the University of Liverpool have found a way of identifying families at high risk of pancreatic cancer.

The team has developed a novel means of testing for pancreatic cancer that will enable doctors to treat the killer disease at its earliest stages. They are also now able to show how the risk of cancer for these patients changes with age.

The Liverpool-based study group known as EUROPAC (European Registry Of Hereditary Pancreatitis And Familial Pancreatic Cancer), working in collaboration with a similar group in Germany, has shown that familial pancreatic cancer develops at an increasingly younger age as it is passed down generations - a phenomenon known as anticipation.

In the largest study of its kind, the team surveyed 600 families with a history of pancreatic cancer and identified a subgroup of over 80 families whose lifetime risk of developing the cancer was 50 per cent.

Dr Bill Greenhalf, from the University's Division of Surgery and Oncology, said: "Of those families with the highest incidence of pancreatic cancer, we found that members developed the disease at a younger age in each generation. As well as giving important clues about the nature of the disease, this allows a more accurate estimate of the risk an individual faces of developing cancer in the short term so we can treat the cancer as soon as possible."

The team led by Dr Greenhalf has developed a novel method of analysing pancreatic juice, taken from patients in families with a history of pancreatic cancer. By analysing DNA scientists are able to identify specific genetic mutations that indicate the chances of a patient developing the disease in the short term, ranging from a 0.1% chance to a 90% certainty.

Dr Greenhalf added: "Our research has provided strong evidence that anticipation and pancreatic juice analysis are the most effective means of screening for pancreatic cancer in families with a history of the disease. We intend to carry out further trials of these techniques and hope the results encourage more widespread adoption of these screening methods."
-end-
The research is published in two separate papers in the academic journals, Gut and Gastroenterology.

Notes to editors

1. The Pancreas Treatment and Research Centre at the University of Liverpool is the largest of its kind in the UK.
2. Cancer of the pancreas is one of the ten most common cancers in Britain, killing 7,000 people every year. It is amongst the most difficult to detect and treat. There are very few early symptoms and so most patients present late. Only 15% of patients are suitable for surgery - the only treatment available - and most sufferers die within a year of diagnosis.
3. The University of Liverpool is one of the UK's leading research institutions. It attracts collaborative and contract research commissions from a wide range of national and international organisations valued at more than £90 million annually.

University of Liverpool

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.